All studies
Phase 2 / Phase 3RecruitingInterventionalNCT04613596

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  • Advanced Non-Small Cell Lung Cancer
  • Metastatic Non-Small Cell Lung Cancer
I want to take partRefer a patient22 sites in India (19 recruiting) · 770 worldwide

At a glance

Phase
Phase 2 / Phase 3
Study type
Interventional
Sponsor
Mirati Therapeutics Inc.
Enrolment target
626
Started
2 December 2020
Main results due (estimated)
31 October 2028
Study ends (estimated)
31 October 2029
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
None
Sites
770 · 22 in India
First posted
3 November 2020
Registry updated
30 October 2026

MRTX849 Monotherapy, MRTX849 in Combination with Pembrolizumab and Pembrolizumab alone

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS
* Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS\>=50%
* Phase 3: Presence of measurable disease per RECIST1.1
* Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following:

  1. No evidence of brain metastases
  2. Untreated brain metastases not needing immediate local therapy
  3. Previously treated brain metastases not needing immediate local therapy

Exclusion Criteria:

* Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510).
* Phase 2: Active brain metastases
* Phase 3: Patients with known central nervous system (CNS) lesions must not have any of the following:

  1. Any untreated brain lesions \> 2.0 cm in size
  2. Any brainstem lesions
  3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions at a total daily dose of \> 10 mg of prednisone (or equivalent) prior to randomization.
  4. Have poorly controlled (\> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain lesions notwithstanding CNS-directed therapy
* Phase 3: Radiation to the lung \> 30 Gy within 6 months prior to the first dose of study treatment

What this study is about

In the sponsor’s own words, from the registry.

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.

The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.

Read the detailed description

The Phase 2 portion of this study will evaluate the efficacy and safety of MRTX849 as monotherapy and in combination with pembrolizumab. There will be 3 cohorts of patients, all of whom have KRAS G12C mutation, have advanced or metastatic NSCLC, and are candidates for first-line treatment. 2 cohorts have PD-L1 TPS score \<1% and are randomized to MRTX849 monotherapy or MRTX849 in combination with pembrolizumab. The 3rd cohort has PD-L1 TPS score of 1% or higher and is treated with MRTX849 and pembrolizumab

The Phase 3 portion of the study will randomize patients with squamous or nonsquamous NSCLC with KRAS G12C mutation and TPS \>=50% in the first-line setting to adagrasib plus pembrolizumab or pembrolizumab. Primary efficacy objective is to compare efficacy between experimental and comparator arms. Secondary and exploratory objectives include evaluation of secondary efficacy endpoints, safety and tolerability, adagrasib PK, PROs, and correlative genomic biomarkers for the combination regimen in the study population.

MRTX849 is an orally available small molecule inhibitor of KRAS G12C, and Pembrolizumab (KEYTRUDA®) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Keywords: KRAS G12C · Non-small cell lung cancer · NSCLC · Metastatic Non-Small Cell Lung Cancer · Adagrasib · Krazati · TPS

What participants receive

  • Experimental

    Phase 2 Cohort 1a: PD-L1 TPS <1%

    Cohort 1a: Adagrasib twice daily (BID) in combination with pembrolizumab

    Drug: Adagrasib

  • Experimental

    Phase 2 Cohort 1b: PD-L1 TPS <1%

    Cohort 1b: Adagrasib BID monotherapy

    Drug: Adagrasib

  • Experimental

    Phase 2 Cohort 2: PD-L1 TPS ≥1%

    Cohort 2: Adagrasib BID in combination with pembrolizumab

    Drug: Adagrasib

  • Experimental

    Phase 3 Cohort 3 Investigational Arm

    Adagrasib BID in combination with pembrolizumab

    Drug: Adagrasib

  • Active comparator

    Phase 3 Cohort 4 Comparator Arm

    Pembrolizumab

    Drug: Pembrolizumab

Interventions

  • AdagrasibDrug

    Also known as Pembrolizumab

    Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)

  • AdagrasibDrug

    Adagrasib 600 mg BID monotherapy (Cohort 1b)

  • AdagrasibDrug

    Also known as Pembrolizumab

    adagrasib 400 mg BID in combination with pembrolizumab

  • AdagrasibDrug

    Also known as Pemrolizumab

    Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W

  • PembrolizumabDrug

    Pembrolizumab 200 mg IV Q3W

What the study measures

Primary outcomes

  1. Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.

    Objective Response Rate (ORR) as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

    Time frame: 22 months

  2. Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab

    Progression Free Survival per RECIST 1.1 by Blinded Independent Central Review (BICR) and Overall Survival

    Time frame: 36 months

Secondary outcomes

  1. Phase 2: To characterize the safety and tolerability of study treatments in selected populations

    Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and laboratory abnormalities.

    Time frame: 22 months

  2. Phase 2: Duration of Response

    Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.

    Time frame: 22 months

  3. Phase 2: Progression Free Survival

    Defined as time from first study treatment until disease progression or death from any cause, whichever occurs first.

    Time frame: 22 months

  4. Phase 2: To evaluate secondary efficacy endpoints using the study treatment in selected populations

    1-Year Survival rate

    Time frame: 12 months

  5. Phase 2: To evaluate secondary efficacy endpoints using the study treatment in selected populations

    Overall Survival (OS)

    Time frame: 22 months

  6. Phase 2: To evaluate the pharmacokinetics (PK) of study treatments by measuring blood plasma MRTX849 and potential metabolite concentrations.

    Pharmacokinetics (PK) Blood plasma Adagrasib and potential metabolite concentrations

    Time frame: 22 months

  7. Phase 3: To evaluate the safety and tolerability in the study population

    Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and laboratory abnormalities.

    Time frame: 36 months

  8. Phase 3: To evaluate health-related quality of life (HRQOL) and lung cancer specific symptoms in the study population

    Patient Reported Outcomes to measure quality of life

    Time frame: 36 months

  9. Phase 3: Progression Free Survival per RECIST 1.1 by Investigator

    Defined as time from first study treatment until disease progression or death from any cause, whichever occurs first.

    Time frame: 36 months

  10. Phase 3: Duration of Response (DOR) per RECIST 1.1 by Investigator and BICR

    Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.

    Time frame: 36 months

  11. Phase 3: Objective Response Rate (ORR) per RECIST 1.1 by Investigator and BICR

    Defined as the percent of patients documented to have a confirmed CR or PR.

    Time frame: 36 months

Who is running it

Lead sponsor
Mirati Therapeutics Inc.
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Mirati Therapeutics Inc.
Data monitoring committee
No
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
CA239-0009
Other IDs
CA239-0009, 849-007, 2023-508922-83, 2023
  • Bristol-Myers Squibb

    Study director

    Bristol-Myers Squibb

Study sites(770)

  • CIMS Hospital

    Ahemdabad, India

    Recruiting

  • KLES Dr. Prabhakar Kore Hospital & Medical Research Centre

    Belagavi, India

    Recruiting

  • Marathwada Cancer Hospital & Research Institute

    Chhatrapati Sambhajinagar, India

    Recruiting

  • Basavatarakam Indo American Cancer Hospital & Research Institute

    Hyderabad, India

    Recruiting

  • Amrita Institute of Medical Sciences & Research Centre

    Kochi, India

    Recruiting

  • Netaji Subhas Chandra Bose Cancer Hospital

    Kolkata, India

    Recruiting

  • Meenakshi Mission Hospital and Research Centre

    Madurai, India

    Recruiting

  • Tata Memorial Centre - Tata Memorial Hospital

    Mumbai, India

    Recruiting

  • Mysore Medical College and Research Institute

    Mysore, India

    Recruiting

  • Indraprastha Apollo Hospitals

    New Delhi, India

    Recruiting

  • Indira Gandhi Institute of Medical Sciences

    Patna, India

    Recruiting

  • Nirmal Hospital Pvt. Ltd.

    Rajkot, India

    Recruiting

  • Mahamana Pandit Madan Mohan Malviya Cancer Centre

    Varanasi, India

    Recruiting

  • Local Institution - 007-1574

    Ahmedabad, India

    Not yet recruiting

  • Local Institution - 007-1586

    Bangalore, India

    Not yet recruiting

  • Local Institution - 007-1587

    Howrah, India

    Not yet recruiting

  • Local Institution - Shetty, R.

    Mangalore, India

    Not yet recruiting

  • Local Institution - 007-1588

    New Delhi, India

    Not yet recruiting

  • Local Institution - 007-1571

    Pune, India

    Not yet recruiting

  • Local Institution - 007-1564

    Hyderabad, India

    Withdrawn

  • Local Institution - 007-1569

    Jaipur, India

    Withdrawn

  • Local Institution - 007-1578

    New Delhi, India

    Withdrawn

  • USOR - Arizona Oncology - Prescott Valley

    Prescott Valley, Arizona, United States

    Recruiting

  • Arizona Clinical Research Center

    Tucson, Arizona, United States

    Recruiting

  • Highlands Oncology Group - Springdale

    Springdale, Arkansas, United States

    Recruiting

  • Providence - Saint Joseph Home Health - Anaheim

    Anaheim, California, United States

    Recruiting

  • The Oncology Institute of Hope and Innovation - Corporate Office

    Cerritos, California, United States

    Recruiting

  • MemorialCare - Long Beach Medical Center

    Long Beach, California, United States

    Recruiting

  • TRIO - Cancer & Blood Specialty Clinic - Los Alamitos

    Los Alamitos, California, United States

    Recruiting

  • San Francisco Veterans Affairs Medical Center

    San Francisco, California, United States

    Recruiting

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California, United States

    Recruiting

  • Providence Medical Group - Santa Rosa

    Santa Rosa, California, United States

    Recruiting

  • Stockton Hematology Oncology Medical Group (SHOMG) - Stockton (Suite B)

    Stockton, California, United States

    Recruiting

  • USOR - Rocky Mountain Cancer Centers - Lone Tree

    Lone Tree, Colorado, United States

    Recruiting

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut, United States

    Recruiting

  • GenesisCare USA

    Aventura, Florida, United States

    Recruiting

  • Bay Pines Veterans Affairs Healthcare System

    Bay Pines, Florida, United States

    Recruiting

  • SCRI - Florida Cancer Specialists - South Region Research Office

    Fort Myers, Florida, United States

    Recruiting

  • 21st Century Oncology of Jacksonville - North Lee Street

    Jacksonville, Florida, United States

    Recruiting

  • Cancer Specialists of North Florida - Southpoint

    Jacksonville, Florida, United States

    Recruiting

Showing 40 of 770 sites. 382 recruiting, 237 not recruiting and 151 cancelled; 22 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes
What is shared
Study protocol, Sap, Csr
When
See Plan Description
Access
See Plan Description

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Source: ClinicalTrials.gov record NCT04613596, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.